Evidence map›Paper›PMID 37967790›Full record

ReviewDrug discovery today2024

Multiorgan locked-state model of chronic diseases and systems pharmacology opportunities.

Choong Yong Ung, Cristina Correia, Hu Li, Christopher M Adams, Jennifer J Westendorf, Shizhen Zhu

Abstract readReview
In one paragraph

Review in Drug discovery today, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Choong Yong UngDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.
Cristina CorreiaDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.
Hu LiDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.
Christopher M AdamsDivision of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, Rochester, MN, USA; Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA.
Jennifer J WestendorfDepartment of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA; Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN, USA.
Shizhen ZhuDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA; Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA. Electronic address: zhu.shizhen@mayo.edu.

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Lila J. Rutten · 1985 to 2026
$151.3M
Peripheral and Central Biomarkers of Alzheimer's Disease in Diverse CohortsU19AG074879 · NIA · MAYO CLINIC JACKSONVILLE · PI Minerva Maria Carrasquillo · 2023 to 2026
$42.0M
Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI SCOTT H KAUFMANN · 2009 to 2026
$37.0M
Capturing the molecular complexity of Alzheimer's disease through the lens of RNA binding proteinsRF1AG056318 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI LI, HU, WOLOZIN, BENJAMIN L · 2018 to 2020
$4.4M
Novel Signaling Pathways Underlying Skeletal Muscle AtrophyR01AG060637 · NIA · UNIVERSITY OF IOWA · PI ADAMS, CHRISTOPHER M · 2018 to 2022
$2.6M
Molecular pathogenesis of skeletal muscle atrophyR01AR071762 · NIAMS · UNIVERSITY OF IOWA · PI ADAMS, CHRISTOPHER M · 2017 to 2021
$2.4M
Phlpp phosphatases in osteoarthritisR01AR078552 · NIAMS · MAYO CLINIC ROCHESTER · PI WESTENDORF, JENNIFER J · 2022 to 2025
$1.9M
Interplay between low levels of GAS7 expression and MYCN overexpression and its impact on neuroblastoma metastasisR01CA240323 · NCI · MAYO CLINIC ROCHESTER · PI ZHU, SHIZHEN · 2020 to 2024
$1.8M
Discovery of Novel Pharmaceutical Agents for Skeletal Muscle AtrophyR44AR069400 · NIAMS · EMMYON, INC. · PI ADAMS, CHRISTOPHER M, EBERT, SCOTT MATTHEW · 2020 to 2021
$1.5M
PHLPP inhibition and Osteoarthritis-Associated PainR21AR082134 · NIAMS · MAYO CLINIC ROCHESTER · PI STAFF, NATHAN P, WESTENDORF, JENNIFER J · 2023 to 2024
$380k
Uncovering therapeutic-associated biomarkers via machine learning and feature engineering approachesR03OD034496 · OD · MAYO CLINIC ROCHESTER · PI LI, HU · 2022 to 2022
$318k
NCI NIH HHS P30 CA015083NCI NIH HHS P50 CA136393NCI NIH HHS R01 CA240323NIAMS NIH HHS R01 AR071762NIAMS NIH HHS R01 AR078552NIAMS NIH HHS R21 AR082134NIAMS NIH HHS R44 AR069400NIA NIH HHS R01 AG060637NIA NIH HHS RF1 AG056318NIA NIH HHS U19 AG074879NIH HHS R03 OD034496
6 · The paper itself

Abstract

With increasing human life expectancy, the global medical burden of chronic diseases is growing. Hence, chronic diseases are a pressing health concern and will continue to be in decades to come. Chronic diseases often involve multiple malfunctioning organs in the body. An imminent question is how interorgan crosstalk contributes to the etiology of chronic diseases. We conceived the locked-state model (LoSM), which illustrates how interorgan communication can give rise to body-wide memory-like properties that 'lock' healthy or pathological conditions. Next, we propose cutting-edge systems biology and artificial intelligence strategies to decipher chronic multiorgan locked states. Finally, we discuss the clinical implications of the LoSM and assess the power of systems-based therapies to dismantle pathological multiorgan locked states while improving treatments for chronic diseases.

Indexed as

Artificial IntelligenceNetwork PharmacologyChronic DiseaseHumansLife Expectancy

Identifiers

PMID37967790
PMCPMC11109989

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.